Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
16 Results for "
PLK4 kinase
" in MedChemExpress (MCE) Product Catalog:
Products (16)
16 Results for "PLK4 kinase" in MCE Product Catalog:
33
Target:
Research Areas:
Centrinone (LCR-263) is a selective and reversible inhibitor of polo-like kinase 4 (PLK4) with a Ki of 0.16 nM.
Cat. No.: HY-172737
CAS No.: 2980682-00-4
Target:
Research Areas:
RP-1664 is a selective and orally active PLK4 inhibitor with an IC50 of 3 nM. RP-1664 demonstrates exquisite selectivity over related kinases, including AURKA/B and PLK1. RP-1664 disrupts centriole biogenesis in cancer cells and leads an accumulation of PLK4 and p21 protein. RP-1664 demonstrates increased sensitivity in TRIM37-high-expressing cells or tumors. RP-1664 exhibits anti-tumor activity in breast cancer and neuroblastoma research [1][2].
Research Areas:
Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
FMF-06-098-1 is a multi-target kinase PROTAC degrader. FMF-06-098-1 can be used to target degradation kinases which degrades AAK1, AΒL2, AURKA, AURKB, BUBIB, CDC7, CDK1, CDK12, CDK13, CDK2, CDK4, CDk6, CDK7, CDK9, CHEK1, CSNKID, EPHA1, PER, FGFR1, GAK, IRAK4, ITK, LIMK2, MAP4K2, MAP4K3, MAPK6, MAPK7, MARK4, MELK, PKN3, PLK4, PRKAA1, PTK2, PTK6, RPS6KA4, S1K2, STK35, TNK2, UHMK1, ULK1, and WEE1 .
Target:
Research Areas:
PLK4-IN-1 is a spiro cyclopropyl indolinone compound and PLK4 inhibitor with inhibitory activity against Aurora A and Aurora B kinases .PLK4-IN-1 can be used for the research of cancer .
Cat. No.: HY-149912
CAS No.: 3016297-55-2
Research Areas:
CZS-241 is an orally active and selective inhibitor of Polo-like Kinase (PLK) 4 (IC50=2.6 nM). CZS-241 inhibits TRKA with an IC50 value of 2.74 μM. CZS-241 induces apoptosis and arrests cell cycle at S/G2 phase. CZS-241 shows highly potent antiproliferative activity against leukemia cell lines, and exhibits safety against normal cell lines .
Cat. No.: HY-134775A
CAS No.: 1247001-86-0
Target:
Research Areas:
PLK4-IN-3 is a less active absolute stereochemistry of PLK4-IN-1. PLK4-IN-1 is a spiro cyclopropyl indolinone compound and PLK4 inhibitor with inhibitory activity against Aurora A and Aurora B kinases .PLK4-IN-1 can be used for the research of cancer .
Cat. No.: HY-120279A
CAS No.: 1169211-37-3
Target:
Research Areas:
CFI-400437 is an indolinone-derived, ATP-competitive kinase inhibitor with high selectivity for PLK4 (IC50 of 0.6 nM) .
Cat. No.: HY-149912A
Research Areas:
CZS-241 hydrochloride is an orally active and selective inhibitor of Polo-like Kinase 4 (PLK4) (IC50=2.6 nM). CZS-241 hydrochloride inhibits TRKA with an IC50 value of 2.74 μM. CZS-241 hydrochloride induces apoptosis and arrests cell cycle at S/G2 phase. CZS-241 hydrochloride shows highly potent antiproliferative activity against leukemia cell lines, and exhibits safety against normal cell lines .
Cat. No.: HY-116190
CAS No.: 1430741-35-7
Target:
Research Areas:
CFI-401870 is an orally active threonine tyrosine kinase (TTK (Mps1)) inhibitor with an IC50 of 3.1 nM. CFI-401870 exhibits IC50s against PLK4, KDR, AURKA and other kinases such as AURKB/INCENP were all greater than 1 μM.CFI-401870 inhibits the growth of various cancer cells, causing chromosome lag, an increase in aneuploidy and cell cycle arrest. CFI-401870 can be used for the study of cancers such as colon cancer .
Cat. No.: HY-162895
NL13 is a Polo-like kinase 4 (PLK4) inhibitor with an IC50 value of 2.32 μM. NL13 can inhibit the viability of PC3 and DU145 prostate cancer cells, with IC50 values of 3.51 μM and 2.53 μM, respectively. NL13 can lead to the inactivation of the AKT signaling pathway by downregulating CCNB1/CDK1, inducing G2/M cell cycle arrest, and triggering apoptosis through the cleavage of caspase-9/caspase-3. In prostate cancer mice, NL13 can inhibit tumor growth .
Cat. No.: HY-P703290
Purity: ≥ 85%, as determined by reducing SDS-PAGE.
Synonyms: PLK4; Non-Specific Serine/Threonine Protein kinase; Prev. STK18; Polo-Like kinase 4 (Drosophila); Serine/Threonine-Protein kinase PLK4; Serine/Threonine kinase 18; Polo-Like kinase 4; Snk Akin kinase; Sak; MCCRP2; Serine/Threonine-Protein kinase Sak; PLK-
Cat. No.: HY-P705861
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: PLK4; Non-Specific Serine/Threonine Protein kinase; Prev. STK18; Polo-Like kinase 4 (Drosophila); Serine/Threonine-Protein kinase PLK4; Serine/Threonine kinase 18; Polo-Like kinase 4; Snk Akin kinase; Sak; MCCRP2; Serine/Threonine-Protein kinase Sak; PLK-
Cat. No.: HY-P72780
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: PLK4; Non-Specific Serine/Threonine Protein kinase; Prev. STK18; Polo-Like kinase 4 (Drosophila); Serine/Threonine-Protein kinase PLK4; Serine/Threonine kinase 18; Polo-Like kinase 4; Snk Akin kinase; Sak; MCCRP2; Serine/Threonine-Protein kinase Sak; PLK-
Species:
Source:
Cat. No.: HY-P71923A
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: PLK4; Non-Specific Serine/Threonine Protein kinase; Prev. STK18; Polo-Like kinase 4 (Drosophila); Serine/Threonine-Protein kinase PLK4; Serine/Threonine kinase 18; Polo-Like kinase 4; Snk Akin kinase; Sak; MCCRP2; Serine/Threonine-Protein kinase Sak; PLK-
Cat. No.: HY-187506
Target:
Research Areas:
ZSL-M028 is an orally active and selective Polo-like kinase 4 (PLK4) inhibitor with an IC50 value of 1.1 nM. ZSL-M028 exhibits anti-tumor activity against TRIM37-amplified neuroblastoma, downregulates SAS6, upregulates FBXW5, induces G2-phase cell cycle arrest and apoptosis, activates the p53 signaling pathway, and inhibits tumor cell colony formation and migration. ZSL-M028 shows significant tumor growth inhibitory activity in the IMR-32 neuroblastoma xenograft model. ZSL-M028 can be used in neuroblastoma-related research .
Cat. No.: HY-184113
Synonyms: DHP
Target:
Research Areas:
Dihydropelitinib (DHP) is a ILK ligand with a Kd value of 252 nM. Dihydropelitinib acts as a cytoskeleton modulator that induces actin (Actin) cytoskeleton rearrangement. Dihydropelitinib exhibits anticancer activity against liver cancer and lung adenocarcinoma. Dihydropelitinib can be used in studies related to liver cancer and lung adenocarcinoma .
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
